Clinical trials: Stroke Prevention
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Atrial Fibrillation
Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist
To obtain a better understanding on the comparative effectiveness of apixaban versus VKA (Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial fibrillation) in a real-life setting.
- Trial name
- PIXI-F (NCT02687854)
- Testing
- Apixaban, Vitamin K antagonist
- Where
- United States
- Volunteers
- 18,591 people
- Sponsor
- Bayer
Cerebral Infarction
Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.
The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in preventing the recurrence of cerebral…
- Trial name
- CSPS (NCT00766545)
- Testing
- cilostazol
- Where
- Japan
- Volunteers
- 1,095 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Cerebral Infarction
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00129805
- Testing
- MCI-9042, Aspirin
- Volunteers
- 1,510 people
- Sponsor
- Tanabe Pharma Corporation
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
- Trial name
- NCT00494871
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- 165 sites in Japan
- Volunteers
- 1,280 people
- Sponsor
- Bayer
Moderate Risk of CVD
A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied but to a lesser extent in patients with moderate levels of cardiovascular risk.
- Trial name
- ARRIVE (NCT00501059)
- Testing
- Aspirin (Acetylsalicylic acid, BAYE4465)
- Where
- 466 sites in United States, Germany and 6 more
- Volunteers
- 12,546 people
- Sponsor
- Bayer
Stroke Prevention in Patients With Atrial Fibrillation
Long Term Open Follow-up With H376/95 vs. Warfarin
The purpose of this study is to evaluate tolerability of long-term treatment with ximelagatran compared to standard treatment with warfarin.
- Trial name
- NCT00206063
- Testing
- EXANTA
- Where
- 19 sites in United States, Belgium and 7 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Non-valvular Atrial Fibrillation (NVAF)
A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under…
- Trial name
- XARIN (NCT03887780)
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939)
- Where
- India
- Volunteers
- 504 people
- Sponsor
- Bayer
Atrial Fibrillation
Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues for stroke prevention…
- Trial name
- SAFARI (NCT01805531)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 411 people
- Sponsor
- Bayer
Stroke, Ischemic
Investigating Adherence to Cereneo Tele-service Support After Clinical Disharge in Stroke Patients
This observational, prospective cohort, pilot study aims at investigating usability, operational, and economical factors around 'traditional' and 'technology-supported' approaches to promote a healthy life-style in stroke…
- Trial name
- NCT04733339
- Testing
- Secondary Prevention
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Cereneo AG
NonValvular Atrial Fibrillation
Eliquis Regulatory Post Marketing Surveillance
The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.
- Trial name
- NCT01885598
- Testing
- Apixaban
- Where
- South Korea
- Volunteers
- 3,335 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and…
- Trial name
- XaMINA (NCT03284762)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 1,216 people
- Sponsor
- Bayer
Stroke
COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke
Primary objective: Comparison of efficacy of the combination therapy (clopidogrel plus aspirin) and the aspirin alone (main comparison) to prevent any recurrent ischemic lesion .
- Trial name
- COMPRESS (NCT00814268)
- Testing
- Clopidogrel, Aspirin
- Where
- South Korea
- Volunteers
- 358 people
- Sponsor
- Sanofi
Hypertension, MTHFR 677 CC or CT Genotype
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
This is a multi-center, randomized, double-blind, double-dummy, controlled clinical trial. This trial will include 32,000 Chinese men and women with hypertension (H-type hypertension), MTHFR 677 CC or CT genotype, elevated plasma…
- Conditions
- Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcy≥10µmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
- Trial name
- CSPPT2-CC/CT (NCT04974138)
- Testing
- Amlodipine besylate, Amlodipine besylate and folic acid
- Where
- 20 sites in China
- Volunteers
- 32,000 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947998
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Warfarin, Antiplatelet drugs
- Where
- United Kingdom
- Volunteers
- 50,299 people
- Sponsor
- Bayer
Atrial Fibrillation
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting
- Trial name
- RIVA-F (NCT02690155)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
- Where
- United States
- Volunteers
- 38,831 people
- Sponsor
- Bayer
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals